companiesCompany
Duality Biotherapeutics
Chinese ADC platform company behind BioNTech's trastuzumab pamirtecan (BNT323/DB-1303) and AI-nominated targets.
DB-1303 (HER2, endometrial phase 3 with BioNTech), DB-1311 (B7-H3), DB-1329 (CDCP1, AI-identified). DITAC linker-payload platform.